Wednesday, 12 August 2020

Takeda strengthens patient offering in India

09 July 2020 | News

Introduces innovative Gastrointestinal portfolio for patients with Inflammatory Bowel Diseases (IBD) and Ulcerative Colitis and Crohn's Disease

Takeda India, part of the Takeda Pharmaceutical Company Limited, a global values-based R&D-driven biopharmaceutical leader, has announced the expansion of its highly innovative portfolio for patients in the country with the launch of Kynteles® (generic name: Vedolizumab) as part of its Gastrointestinal (GI) portfolio. GI is Takeda's second therapeutic area in India after Rare Diseases (Haematology, Genetic Diseases, and Immunology).

Kynteles® is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn's Disease (CD). Kynteles®, more widely known as Entvyio®, has shown favourable safety and efficacy results in treating patients suffering from moderate to severe IBD.

Speaking about the launch, Koki Sato, Country Head, Takeda India, said, "At Takeda, we are continuously working towards developing innovative medicines to considerably improve the quality of life of patients. The launch of our highly innovative GI portfolio is a testimony of our commitment to India and patients living with diseases like UC and CD. Patient access to Kynteles® will further augment our vision of providing additional and innovative treatment options to HCPs treating UC and CD."

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account